Svenska
MENUMENU

“Pancreatic cancer is one of the most aggressive and difficult cancers to diagnose. When detected at an early stage, 5-year survival rates are greatly improved; however, currently, most diagnosed cases are in late stages. It is for this and other reasons that a test for early detection is critical. Immunovia’s IMMray™ PanCan-d has the potential of being such tool, and we are looking forward to be part of this large validation study to reveal its clinical value.”
Dr. Randall Brand, Director, GI Malignancy Early Detection, Diagnosis and Prevention Program at University of Pittsburgh.

MOVIE
Immunovia and
IMMray™ technology
(10 min)


Financial reports

November 2018

Immunovia AB published the company’s Interim Report January-September 2018 on Wednesday, November 7, 2018, at 08:30 a.m. CET.

Financial reports

Calendar

19 November, 2018
Financial Meetings Øresund – Sverige fortsatt starkt för Life Science?
Place: Lund, Sweden
5 February, 2019
International Cancer Day 2019
Place: Stockholm, Sweden
13-14 March, 2019
4th International conference on Pancreatic Cancer and Liver diseases
Place: London, UK
All events
Subscribe

Subscribe to receive press releases and reports via email
To start your subscription you need to activate your e-mail address by clicking the link in the email that is sent to you after you have submitted this form.

Press releases
Financial reports